FERRIC HYDROXIDE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Fe.3HO
Molecular Weight	106.867
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[OH-].[OH-].[OH-].[Fe+3]

InChI

InChIKey=MSNWSDPPULHLDL-UHFFFAOYSA-K

InChI=1S/Fe.3H2O/h;3*1H2/q+3;;;/p-3

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Fe
Molecular Weight	55.845
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://books.google.ru/books?id=vxtxWneRBN4C&pg=PA1103&#v=onepage&q&f=falsehttps://mistralhowto.wordpress.com/2012/03/12/what-is-pigment-yellow-42-and-what-is-it-used-for/ | http://sensientfoodcolors.com/en-us/confection/iron-oxides-approved-by-the-fda/ | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=73.2250 | https://www.drugs.com/inactive/ferric-oxide-yellow-381.htmlhttp://www.mfc.co.jp/english/eng/product/sanferol/pdf/fls_gras_notice.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdfhttps://cameochemicals.noaa.gov/chemical/3468 | https://www.ncbi.nlm.nih.gov/pubmed/2135524http://www.edta-chelate.com/ferric-ammonium-edta-liquid--1640836.htmlhttps://books.google.ru/books?id=3hLmyma2-MsC&pg=PA241&lpg=PA241&dq=FERRIC+AMMONIUM+CHLORIDE retrieved from A Consumer's Dictionary of Cosmetic Ingredients, 7th Edition: Complete Information About the Harmful and Desirable Ingredients Found in Cosmetics and Cosmeceuticals By Ruth Winterhttps://www.ncbi.nlm.nih.gov/pubmed/27995746 | http://onlinelibrary.wiley.com/doi/10.1002/047084289X.rn01568/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=
Curator's Comment: description was created based on several sources, including http://www.mfc.co.jp/english/eng/product/sanferol/index.html

Ferric bromide, red-brown odorless compound, an oxidizing reagent, used as a catalyst for organic reactions, particularly in bromination of aromatic compounds.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
transformed cell apoptotic process 106 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21121365	Activator 1404
Phosphate 43 Target ID: CHEMBL2364184 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdf	Chelating Agent 143

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2554
Unknown 2554
Dental diseases 44 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13224146 https://www.ncbi.nlm.nih.gov/pubmed/286710	Primary	Basic research	Unknown Approved Use Unknown
Iron deficiency anemia 55 Sources: http://www.mfc.co.jp/english/eng/product/sanferol/page/3_11.html	Primary	Approved 8307	SANFEROL Approved Use It has also been reported that SFC preparation improved iron deficiency in a pregnant woman with iron deficiency anemia whose hemoglobin level had not increased after administration of other iron preparations such as ferrous fumarate. A dairy supplemental dose of SFC improved iron deficiency in young women with iron deficiency.
Unknown 2554
Pain 607 Sources: https://www.drugs.com/inactive/ferric-oxide-yellow-381.html https://www.drugs.com/imprints/op-40-16159.html	Inactive ingredient	Approved 8307	Oxycontin Approved Use OxyContin is used in the treatment of chronic pain; pain and belongs to the drug class narcotic analgesics. Launch Date 9.0935997E11
Unknown 2554
Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination 43 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021626lbl.pdf	Curative	Approved 8307	RADIOGARDASE Approved Use Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date 1.06496642E12
Chronic kidney disease 56 Sources: https://www.drugs.com/pro/ferric-citrate-tablets.html	Palliative	Approved 8307	AURYXIA Approved Use Ferric Citrate is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Launch Date 1.40978881E12

PubMed

Title	Date	PubMed
[Effects of ferric fluoride compounds on dental enamel].	1954 Nov 15	13224146
The formation of ferritin from apoferritin. Kinetics and mechanism of iron uptake.	1972 Jan	5075227
The formation of ferritin from apoferritin. Catalytic action of apoferritin.	1973 Oct	4797166
Biological availability of iron supplements for rats, chicks and humans.	1976 Feb	1249649
Contact dermatitis to yellow iron oxide.	1985 Aug	4064645
Carcinogenicity studies on natural and man-made fibres with the intraperitoneal test in rats.	1989	2744824
Effect of physical exercise and vitamin C on absorption of ferric sodium citrate.	1996 Dec	8970140
New phosphate binding agents: ferric compounds.	1999 Jun	10361865
Non-invasive and non-destructive micro-XRF and micro-Raman analysis of a decorative wallpaper from the beginning of the 19th century.	2007 Feb	16838156
Interaction of omapatrilat with FD&C Blue No. 2 lake during dissolution of modified release tablets.	2007 Jul 18	17398043
Metal-mediated cyclization of aryl and benzyl glycidyl ethers: a complete scenario.	2008 Dec 17	19053452
Fabrication of FeF3 Nanoflowers on CNT branches and their application to high power lithium rechargeable batteries.	2010 Dec 7	20954196
Thermal behavior study and decomposition kinetics of amiodarone hydrochloride under isothermal conditions.	2011 Jun	21449701
Oxidative aromatic C-N bond formation: convenient synthesis of N-amino-3-nitrile-indoles via FeBr3-mediated intramolecular cyclization.	2011 May 21	21451828
Finnish wallpaper pigments in the 18th-19th century: presence of KFe3(CrO4)2(OH)6 and odd pigment mixtures.	2013 Apr	23376265
FeF(3) catalyzed cascade C-C and C-N bond formation: synthesis of differentially substituted triheterocyclic benzothiazole functionalities under solvent-free condition.	2014 May	24504377
Heme Binding by Corynebacterium diphtheriae HmuT: Function and Heme Environment.	2015 Nov 3	26478504
Nazarov cyclization of 1,4-pentadien-3-ols: preparation of cyclopenta[b]indoles and spiro[indene-1,4'-quinoline]s.	2016 Feb 14	26771024
Mechanisms and origins of the switchable regioselectivity of FeBr3-catalyzed [1,2]-aryl and [1,2]-alkyl shifts of α-aryl aldehydes.	2016 Feb 28	26822257
Halide Influence on Molecular and Supramolecular Arrangements of Iron Complexes with a 3,5-Bis(2-Pyridyl)-1,2,4,6-Thiatriazine Ligand.	2016 Jun 6	27152549
Iron-Catalyzed Regioselective Transfer Hydrogenative Couplings of Unactivated Aldehydes with Simple Alkenes.	2016 May 17	27072872
Phosphorus recovery from biogas slurry by ultrasound/H(2)O(2) digestion coupled with HFO/biochar adsorption process.	2017 Feb	27594573
A Simplified Fe-Based PhotoATRP Using Only Monomers and Solvent.	2017 Jul	27995746

Patents

Sample Use Guides

In Vivo Use Guide

As a food supplement, ferric sodium pyrophosphate is administered orally.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 16 19:18:16 UTC 2022` Edited by `admin` on `Fri Dec 16 19:18:16 UTC 2022`
Record UNII	2UA751211N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FERRIC HYDROXIDE

Common Name

English

IRON HYDROXIDE (FE(OH)3)

Common Name

English

HYDRATED IRON SESQUIOXIDE

Common Name

English

FERRIC HYDROXIDE GEL

Common Name

English

Ferric hydroxide [WHO-DD]

Common Name

English

DIIRON TRIOXIDE HYDRATE

Common Name

English

Classification Tree Code System Code

WHO-ATC

B03AB04